Almirall Q1 2026 slides: biologics surge offsets modest revenue miss

Almirall reported Q1 2026 net sales of €291.0 million, just below the €294.15 million consensus, but still up 2.2% year over year with EBITDA of €67.5 million and a 23.2% margin. Growth was driven by European dermatology, where sales rose 19.3%, led by Ebglyss (€41.9 million, more than doubled) and Ilumetri (€61.6 million, +11.8%), while US sales fell 29.1%. Management reaffirmed full-year 2026 guidance and highlighted pipeline expansion plus a new Huaota collaboration, though gross margin pressure from royalties and a negative free cash flow of €24.0 million remain headwinds.

Analysis

The market is likely underpricing the quality of the mix shift: this is no longer a broad-based pharma story, it is becoming a concentrated dermatology royalty/launch execution story. That matters because the earnings stream is increasingly levered to a small number of branded assets, which improves operating leverage on upside but also makes quarterly noise from milestones, royalties, and launch phasing more visible than headline sales growth suggests.

The real second-order effect is competitive: stronger Ebglyss and Ilumetri uptake tightens the strategic window for peers in dermatology to defend share, especially in biologics-heavy categories where prescriber switching is sticky once efficacy data accumulates. If the pediatric and maintenance datasets translate into payer acceptance, the company can extend duration curves and lower churn, which is more valuable than near-term unit growth because it supports a higher terminal multiple and better visibility on peak sales.

The main risk is that margin expansion may lag revenue growth for the next 2-3 quarters because the royalty base rises before the full benefit of scale and lifecycle expansion is realized. In other words, the stock can sell off on “good” quarters if EBITDA doesn’t inflect as fast as the market expects. The balance sheet reduces financing risk, but it also means the market will start valuing capital allocation discipline: any M&A or licensing misstep would be punished if it distracts from the biologics ramp.

Contrarian take: consensus is probably too focused on the modest revenue miss and not enough on the durability of the European dermatology franchise. If the next catalyst set includes regulatory progress in pediatric AD or psoriatic arthritis, the narrative can re-rate on pipeline optionality rather than just current-year earnings. The trade is less about this quarter and more about whether management can convert a promising franchise into a multi-year compounder before the market fully prices in the peak-sales trajectory.

Key Decisions for Investors

• Long ALM on 3-6 month horizon on weakness after earnings: risk/reward favors owning the franchise while the market digests temporary royalty drag; use a stop below the post-print low if the next update shows no acceleration in dermatology growth.
• Pair trade: long ALM / short a European generic-heavy pharma basket over the next 1-2 quarters, betting that branded biologics momentum and pipeline optionality outperform businesses exposed to pricing pressure and slower growth.
• Buy optionality around the next clinical/regulatory catalyst: small-size call spreads in ALM expiring 6-9 months out to capture a re-rating if pediatric expansion or psoriatic arthritis progress is validated.
• Avoid chasing the move if the stock gaps higher on pipeline headlines; wait for a pullback because near-term EBITDA can still underwhelm while royalties and milestone timing remain noisy.
• If management signals M&A or larger licensing spend, consider trimming longs or hedging with sector exposure, as the balance sheet is strong but the market will demand disciplined deployment rather than empire-building.